TrialsgrambetaRCTs are beautiful

MASAI

2023

Mammography Screening with Artificial Intelligence trial

In 105,934 women in population-based mammography screening, AI-supported screen reading was non-inferior to standard double reading without AI for interval cancer rate, with higher cancer detection and a 44.2% lower screen-reading workload.

Result

Efficacy: Interval cancer rate (20% non-inferiority margin)ratio 0.88 (95% CI 0.65-1.18)

Below 1 favours AI-supported screen reading, above 1 favours standard double reading without AI.

Event rates AI-supported screen reading 1.55 vs standard double reading without AI 1.76 per 1,000

Also reported: Sensitivity 80.5% vs 73.8% (P=0.031), specificity 98.5% in both. Cancer detection 6.4 vs 5.0 per 1,000 (ratio 1.29, 95% CI 1.09–1.51; P=0.0021); screen-reading workload −44.2%. Interim safety analysis in 80,033 women: detection 6.1 vs 5.1 per 1,000 (ratio 1.2, 95% CI 1.0–1.5), workload −44.3%.

Original publication
Subtopic
AI-supported double reading
Design
Population-based single-blinded non-inferiority RCT, Sweden
Relevance
Practice-defining: a trial the field needs to know.
Source
Lång K, et al. Lancet Oncol. 2023;24(8):936-944; Hernström V, et al. Lancet Digit Health. 2025;7(3):e175-e183; Gommers J, et al. Lancet. 2026;407(10527):505-514.doi 10.1016/S1470-2045(23)00298-X

Discussion & critique

The first randomised trial of AI in mammography screening and the anchor of the cluster: AI triage nearly halved radiologist reading with no loss of safety, more (mostly small, node-negative) cancers detected, and a non-inferior interval cancer rate at two years. One AI system (Transpara) at four sites of one Swedish programme with double reading as comparator, so the result does not transfer directly to single-reader programmes; whether earlier detection lowers breast cancer mortality is beyond the trial. PRAIM and ScreenTrustCAD are the non-randomised companions.